Zydus Lifesciences has launched Anira, a biosimilar to Regeneron Pharmaceuticals’ aflibercept 2 mg, which is indicated for certain eye diseases. Zydus on Thursday said Anira is India’s first indigenously developed biosimilar of Aflibercept 2 mg, while announcing that it has also signed an agreement with Regeneron Pharmaceuticals and Bayer. Anira is indicated for the treatment of neovascular (wet) age-related macular degeneration, visual loss due to macular edema due to retinal vein occlusion, visual loss due to diabetic macular edema (DME), and certain other conditions.

Collectively, the conditions represent a large patient group that requires timely anti-VEGF therapy to prevent irreversible vision loss. Since chronic retinal diseases require repeated intravitreal injections over extended periods, affordability and sustainability of treatment is a concern, the company said. Sharvil P.

Patel, Managing Director, Zydus Lifesciences, said, “Anya is a game-changer for affordable retinal care in India. By providing high-quality, indigenously developed Aflibercept 2 mg, we are expanding patients’ access to breakthrough treatments with advanced biologics.

“.